EUCTR2006-005774-50-GB进行中（未招募）1 期
Protocol for taking pharmacogenetic testing of tacrolimus into the clinical arena: patient tailored anti-rejection therapy
Central Manchester & Manchester Children's University Hospitals NHS Trust0 个研究点目标入组 400 人开始时间: 2006年12月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects who have undergone a kidney transplant and are receiving oral tacrolimus as part of their clinical management
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any form of substance abuse (including drug or alcohol abuse) psychiatric disorder or condition which, in the opinion of the investigator, may invalidate the patient's ability to give informed consent.
研究者
相似试验
招募中
不适用
Implementation of pharmacogenetic testing at the Robert-Bosch-KrankenhausDiseases that are to be treated with a drug for which a PGx guideline has been publishedDRKS00019021Robert Bosch Gesellschaft für medizinische Forschung mbH (RBMF)100
尚未招募
不适用
Pharmacogenetic testing in the clinical setting: is screening for TPMT genotype a cost-effective treatment strategy? The first prospective randomized controlled trial within the Dutch health care system.Inflammatory Bowel DiseaseNL-OMON30092Zorgonderzoek Nederland (ZON)1,000
招募中
不适用
PREemptive pharmacogenomic testing for Preventing Adverse drug REactionsbijwerkingenAdverse drug reactionsNL-OMON50620eids Universitair Medisch Centrum1,450
进行中（未招募）
不适用
Clinical trial to assess the pharmacokinetic/Pharmacodynamic characteristics and safety/tolerability of CKD-519 new formulation in healthy male subjectsEndocrine, nutritional and metabolic diseaseKCT0001729Chong Kun Dang30
进行中（未招募）
不适用
comparison of genetic make up based warfarin dose versus the standard dose of warfarin in asian patientsCTRI/2022/07/043907Amol N Patil